Quick Answer
SAB Biotherapeutics, Inc. reported Total Assets of $172.81 million for the year ending 2025.
- SAB Biotherapeutics, Inc. showed an increase of +291.0% in Total Assets from 2024 to 2025.
- This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $117.27 million | Q2 2021: $117.09 million | Q3 2021: $116.93 million | Q3 2022: $52.51 million | Q1 2023: $42.67 million | Q2 2023: $35.44 million | Q3 2023: $28.34 million | Q1 2024: $71.37 million | Q2 2024: $61.89 million | Q3 2024: $53.80 million | Q1 2025: $38.12 million | Q2 2025: $30.13 million | Q3 2025: $183.45 million.
- Over the full 8 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Total Assets has grown by 205.7%.
- Historical annual values: Fiscal year 2025: $172.81 million | Fiscal year 2024: $44.20 million | Fiscal year 2023: $83.94 million | Fiscal year 2022: $50.90 million | Fiscal year 2022: $59.41 million | Fiscal year 2022: $68.49 million | Fiscal year 2021: $81.14 million | Fiscal year 2020: $56.54 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: